Moderna Stock News

Omicron may move the world rapidly to an endemic phase, said Moderna chief Stephane Bancel.

The efficacy of boosters against Covid-19 is likely to decline and people may need another shot in the fall of 2022, Moderna CEO Stephane Bancel says.

Stephane Bancel, the CEO of vaccine maker Moderna (MRNA) expects that a second COVID-19 booster might be required this fall as the vaccines efficacy decline over the next few

Boosters will likely protect people through the current Omicron surge, Moderna''s Stephane Bancel said. But their efficacy will probably wane in the months ahead.

Moderna CEO says company is working on vaccine to battle Omicron variant of COVID-19, booster may be needed in fall

CNBC carries the report. Moderna CEO Stephane Bancel on Thursday said the efficacy of boosters against Covid-19 will likely decline over time, and people may need a fourth shot in the fall of 2022 to increase their protection. More at that link above. --- ps. Israel is already providing a fo

Finding Chinas answer to Moderna comes with huge health warnings for investors. The $87 billion biotechnology giants Covid-19 vaccines have inspired copycats in the Peoples Republic, where cities like Xian are scrambling to contain fresh outbreaks. With foreign jabs yet to be approved, Shenzhen-listed Walvax Biotechnology and its smaller partner look promising. Their feverish valuations leave little room for error.

Toronto, Jan. 05, 2022 (GLOBE NEWSWIRE) -- North York General Hospital (NYGH), Seneca and the North York Toronto Health Partners are once again partnering to open a COVID-19 vaccination clinic to serve North York residents. Beginning this week, anyone aged 30 or older who is eligible to receive their third dose will be able to book an appointment at the clinic, located at Seneca''s Newnham Campus. "With the rapid spread of Omicron, NYGH and our partners are answering the call to support our community by expanding vaccination," says Karyn Popovich, President and CEO of North York General Hospital. "Thank you to Seneca, fellow members of the North York Toronto Health Partners, and the entire NYGH vaccination team who worked around the clock to make this clinic happen. Getting vaccinated along with our daily safety measures are the most effective ways to protect ourselves and those we love from this tricky virus." Those 30 and over are encouraged to book first and second doses at the NYGH Seneca site clinic as well.

Moderna may have produced one of the worlds biggest medical products in creating an effective vaccine for Covid-19, but it has also landed itself with a problem a bit like the one facing $1.2 trillion electric-vehicle maker Tesla . Modernas market capitalization has rocketed, but only a fraction of its current worth reflects the value of products it actually makes today. The rest is made up of faith in markets yet to exist.

Shares of Moderna Inc. undefined were down 0.5% in premarket trading on Wednesday after the company said it began dosing participants in a Phase 1 clinical

After dropping from record highs in August 2021, now may be a good time to assess Moderna''s long-term value.

The winners on the first trading day of 2021 mostly went on to outperform the S&P 500. The losers did not.

The number is roughly in line with company estimates, but the stock keeps falling.

Moderna Inc. said in a letter to shareholders disclosed Tuesday, Chief Executive Stéphane Bancel said the biotechnology company had shipped about 800 million doses of its COVID-19 vaccine to more than 60 countries in 2021, and more than tripled the amount of cash and cash equivalents it held. Meanwhile, the stock dropped 1.2% in premarket trading, after dropping 7.5% on Monday, and tumbling 27.9% in December. Bancel said the company had more than $17 billion in cash and cash equivalents at the end of 2021, after entering the year with about $5.25 billion. The company said it was working with the U.S. Food and Drug Administration to have its COVID-19 vaccine authorized for 12 to 17 year olds, as it is already authorized in more than 10 countries and the European Union. Separately, Bancel said Moderna''s flu vaccine has showed "positive" interim Phase 1 data, its vaccine for respiratory syncytial virus (RSV) moved to a Phase 2/3 trial and that its Personalized Cancer Vaccine Phase 2 trial is fully enrolled with a readout expected as early as the fourth quarter of 2022.